@article{2cba158d7ebd4e21a608d5b1264ce4a5,
title = "Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial",
abstract = "OBJECTIVE: Palivizumab reduces respiratory syncytial virus (RSV) hospitalization in children at high risk by approximately 50% compared with placebo. We compared the efficacy and safety of motavizumab, an investigational monoclonal antibody with enhanced anti-RSV activity in preclinical studies, with palivizumab. METHODS: This randomized, double-blind, multinational, phase 3, noninferiority trial assessed safety and RSV hospitalization in 6635 preterm infants aged",
keywords = "Antibodies, Monoclonal, Antiviral Agents, Child, Preschool, Confidence Intervals, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Female, Follow-Up Studies, Hospitalization, Humans, Infant, Infant, Newborn, Infant, Premature, Kaplan-Meiers Estimate, Male, Primary Prevention, Probability, Respiratory Syncytial Virus Infections, Risk Assessment, Survival Rate, Treatment Outcome",
author = "Xavier Carbonell-Estrany and Sim{\~o}es, {Eric A F} and Ron Dagan and Hall, {Caroline B} and Brian Harris and Micki Hultquist and Connor, {Edward M} and Losonsky, {Genevieve A} and NN NN and Valerius, {Niels Henrik}",
year = "2009",
doi = "10.1542/peds.2008-1036",
language = "English",
volume = "125",
pages = "e35--51",
journal = "Pediatrics",
issn = "1098-4275",
publisher = "American Academy of Pediatrics",
number = "1",
}